AGM presentation
Released
Released
Announcement PDF
Imagion Biosystems
Limited (ASX:IBX) AGM PRESENTATION
28TH MAY 2021
www.imagionbiosystems.com
Imagion Biosystems – at a glance
New medical imaging technologies for the early detection of cancer
Imagion Biosystems
ASX:IBX
Australian Medical Device Company developing
bio-safe medical imaging technologies.
• Innovative medical imaging using magnetic nanoparticles to identify and
stage cancer early
Market cap: ~$135.3 million
Cash at 31 Mar 2021: $13.007 million
• Proprietary MagSense® technology is non-invasive and provides more specific
& sensitive detection for cancer than current imaging technologies
R&D operations: San Diego
Registered office: Melbourne
Recent Milestones:
May 2021
First patient enrolled in Phase I breast cancer
study
Apr 2021
Brain cancer collaboration with Patrys
Mar 2021
CSIRO Grant to fund prostate cancer
collaboration with Monash University
Nov 2020
$6 million placement
Oct 2020
HREC approval received for Phase I Study
May 2020
Research Collaboration with Siemens
July 2019
Received “Breakthrough Device” designation
by U.S. FDA
• Multiple commercial opportunities:
• Proprietary MagSense® imaging technology
• Magnetic Resonance Imaging (MRI) contrast agent
• Therapy and/or drug delivery
• MagSense® technology complements
existing imaging and is more cost
effective than many existing imaging
technologies
• First-in-human studies initiated in Dec
2020 – targeting metastatic breast
cancer
Patents are already issued, or are pending, in all the
major markets, making the lions share of the global
markets available for commercialization.
Patents are valid through 2029.
IMAGIONBIOSYSTEMS.COM | 2
MagSense® - A new approach to medical imaging
Imagion’s technology will transform cancer diagnosis
•
Non-invasive – a safe and non-surgical solution to detect cancer
•
No radioactivity - uses bio-safe magnetic nanoparticles to “tag” cancer
cells
•
Platform technology – can be used for many cancers as well as other
diseases, e.g. infection and cardiovascular
•
Proprietary - patents issued in most major global markets
•
Breakthrough - technical feasibility and safety profile vetted,
designated as a “Breakthrough Device” by FDA
•
First indication – metastatic breast cancer, provides shortest path to
commercialization
•
First-in-human – initiated first clinical study - a catalyst for valuation
and partnering
IMAGIONBIOSYSTEMS.COM | 3
IMAGIONBIOSYSTEMS.COM | 3
Clear unmet medical need
50 years since last new imaging technology was introduced
X-RAY
(MAMMOGRAPHY)
1913
•
•
•
Best used for finding
structural anomalies
(e.g. broken bones),
and chest X-rays
Mammography used
for screening for
breast cancer
Risks include
exposure to
carcinogenic ionizing
radiation
ULTRASOUND
1956
•
•
•
Inexpensive and fast
method to look at human
organs and areas of
inflammation
Used to guide needle
biopsies and detect
ovarian cancer
Poor sensitivity to
detecting tumors –
tumours must be billions
of cells in size
MAGNETIC RESONANCE (MRI)
1971
•
•
•
Best for imaging soft tissue
including ligaments,
tendons, the brain, and
many internal organs
Used for detecting brain
cancers
Scans can be long and
claustrophobic
COMPUTED TOMOGRAPHY
(CT)
1972
•
•
•
•
Better for imaging the
lungs than MRI
Scan times shorter than
MRI
Used in staging solid
tumors, guiding biopsy
Exposes patients to
carcinogenic ionizing
radiation
POSITRON EMISSION
TOMOGRAPHY (PET)
1973
•
•
•
•
Can be expensive and poorer
resolution than MRI or CT
Better sensitivity for
identification of metastatic
lesions
Subject to significant offtarget and high background
signals
Requires use of radioactive
tracer exposing patients to
radiation
“Despite technical advances in many areas of diagnostic radiology, the
detection and imaging of human cancer remains poor. “
Journal of Clinical Oncology, 2008 New Technologies for Human Cancer Imaging Vol 26 No 24
IMAGIONBIOSYSTEMS.COM | 4
Broad Commercial Applicability
May be used for many types of cancer and at multiple stages of diagnosis
MAGSENSE ® NANOPARTICLES
• Are bio-functionalized to ensure high specificity for
targeting different types of cancers, or other diseases.
• Can be used at multiple stages including primary
diagnosis, staging, and monitoring the effectiveness of
therapy.
• Are compatible with Imagion’s proprietary MagSense®
technology and with existing installed MRI systems as
an MRI contrast agent.
• Uses known safe materials, including iron-oxide cores
which are already cleared for multiple clinical uses
including therapeutic applications.
MULTIPLE CLINICAL TARGETS
Brain
cancer
Breast
cancer
Lung
cancer
Ovarian
cancer
Prostate
cancer
IMAGIONBIOSYSTEMS.COM | 5
2020-2021 Key Achievements
MagSense® enters the clinic
•
•
•
•
•
•
HREC approval for Phase I
study in Australia
Collaboration with Siemens
Healthineers adds exploration
of MRI utility
MagSense® imaging agent
manufacturing for study
completed
Monash Health signed as first
clinical site
Study open for enrolment in
Dec 2020
First patient enrolled
Technology pipeline advancements
•
•
•
•
University of Sydney research
demonstrates utility of IBX
nanoparticles with ultra-low field
magnetic resonance imaging (ULF
MRI)
Boston University collaboration
explores next generation
magnetic sensors to enable
doctor’s office platform
$50k CSIRO grant kick-starts
prostate cancer research with
Monash University
Collaboration with Patrys
(ASX.PAB) targets brain tumour
imaging
Corporate Milestones
•
$14.8 million funds raised
•
$2.2 million R&D Tax Refund
•
Appointment of Dianne
Angus to Board of Directors
•
Appointment of Geoff Hollis
as CFO and Company
Secretary (based in
Melbourne)
IMAGIONBIOSYSTEMS.COM | 6
Study Update
A first-in-human study of a targeted MagSense® imaging agent
01
PHASE I
STUDY
•
First Patient enrolled
•
Multiple sites actively screening patients
•
Study aims to assess safety, tolerability, and
potential effectiveness of the MagSense® imaging
agent
02
PROACTIVE
WORK
STUDY
TIMING
•
Added Clinical Operations personnel in Australia
•
Expanding clinical sites nationally to access more
patients
•
Creating awareness communication campaigns for
patients and doctors
03
•
Expect a total of ~ 15 patients to be enrolled
•
Aim to complete enrolment in 2021 based on
patient availability and number of sites
A platform for growth
Significant potential opportunities in biomedical applications of magnetic nanoparticles as
results develop
CANCER SCREENING
Magnetic nanoparticles are used to
collect/separate tumor cells
and cancer DNA from blood
• Breast Cancer
DIAGNOSTIC IMAGING
MagSense®nanoparticles
are used for diagnosis
and staging of cancers
• Brain Cancer
• Prostate Cancer • Ovarian Cancer
TREATMENTS
Magnetic nanoparticles can be
used for treatment by
hyperthermia or used as an
adjuvant to deliver cancer drugs
or vaccines
IMAGIONBIOSYSTEMS.COM | 8
Pre-Clinical Initiatives
Expanding MagSense® technology towards the diagnosis of other important cancers
Prostate Cancer
Brain Cancer
• Preclinical research project with Monash
University’s Biomedicine Discovery Institute with
the aim of achieving an early proof of concept
validation of MagSense® as a prostate cancer
imaging agent
• Research program aims to pair the targeting capabilities
of Patrys’ deoxymabs with the imaging capabilities of
MagSense® technology to provide a highly effective
imaging agent for hard-to-diagnose cancers such as
brain cancer.
• IBX received $50,000 CSIRO Federal
Government Grant for prostate cancer project.
“Prostate cancer imaging is an evolving field.
Imagion’s new imaging technology would allow
precision mapping of the lymph nodes, identifying
smaller foci of cancer that current imaging
modalities are unable to identify.”
PROFESSOR LISA HORVATH
SCIENTIFIC ADVISORY BOARD MEMBER
• Collaboration with Patrys Limited (ASX.PAB)
“We are very excited to be further leveraging the
cancer-targeting ability deoxymabs by partnering
with Imagion and its innovative MagSense®
imaging technology to potentially develop new
ways to visualize and diagnose cancer.”
DR JAMES CAMPBELL
CEO AND MANAGING DIRECTOR
IMAGIONBIOSYSTEMS.COM | 9
A Path to Growth and Value
Strategic plan provides path to future products and shareholder value
STAGING
BREAST
CANCER
TUMOR
DETECTION
MRI
CONTRAST
TREATMENT
MONITORING
DOCTORS
OFFICE
DETECTION &
THERAPY
Reduce unnecessary
surgery.
Addressable
Market:
$700 million
Breast, prostate,
lung & ovarian.
Safer alternative to
current product,
Gadolinium.
Monitor tumor
size and adjust
treatment
accordingly.
Hand-held
MagSense®
instrument.
Provide both
detection & delivery
of therapy.
Addressable
Market:
$7 billion
Addressable
Market:
>$3 billion
Addressable
Market:
>$2 billion
Addressable
Market:
>$14 billion
Addressable
Market:
>$140 billion
Capital Structure
Well funded throughout 2021 into 2022
•
•
•
2021 cash flows funded by cash
reserves, exercise of listed options
and R&D tax incentive
Ordinary shares on issue
1,041 million
Listed and unlisted options
(26 May 2021)
353 million
Increasing cash inflows from exercise
of listed options with $1.3 million
received in Q1 2021
Share price
(26 May 2021)
$0.13
12-month range
$0.025 - $0.225
Widely held register with strong
relative liquidity
Average daily volume
(12 months to 26 May 2021)
11.1 million shares
Market capitalization
(26 May 2021)
$135.3 million
Cash
(31 March 2021)
$13.0 million
Listed options exercised
(Jan-Mar 2021)
$1.3 million
Shareholder data
(26 May 2021)
Top 20 shareholders own 20.7%
IMAGIONBIOSYSTEMS.COM | 11
Backed by strong industry and clinical experience
BOARD OF DIRECTORS
SCIENTIFIC ADVISORS
ROBERT PROULX
Chairman & CEO
MICHAEL HARSH
Non-Exec Director
JOVANKA NAUMOSKA
Non-Exec Director
DAVID LUDVIGSON
Non-Exec Director
DIANNE ANGUS
Non-Exec Director
MARK VAN ASTEN
Non-Exec Director
DR JOHN HAZLE
MD Anderson Cancer
Center
PROF LISA HORVARTH DR PAUL GRINT
Chris O’Brien Lifehouse Cardea Bio
DR ROBERT IVKOV
Johns Hopkins Univ
PROF ANDREW SCOTT
AM ONJRC
Austin Hospital
IMAGIONBIOSYSTEMS.COM | 12
DISCLAIMER
This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an
offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Imagion or any member of its group nor should it or any part of it form the basis of, or be relied on in connection
with, any contract to purchase or subscribe for any securities of Imagion or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment
whatsoever.
This presentation is not a Prospectus and contains summary information about Imagion and its activities, which is current as at the date of this presentation. The information included in this presentation is of a
general nature and does not purport to be complete nor does it contain all the information which a prospective investor should consider when making an investment decision. Each recipient of this presentation
should make its own enquiries and investigations regarding all information in this presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of
Imagion and the impact that different future outcomes may have on Imagion. This presentation has been prepared without taking account of any person’s investment objectives, financial situation or particular
needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, make their own
assessment of the information and seek legal, financial, accounting and taxation advice appropriate to their jurisdiction in relation to the information and any action taken on the basis of the information.
Imagion is an early stage medical technology company and has so far has not conducted research in human subjects.
The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may
change materially. Unless required by applicable law or regulation, no person (including Imagion) is under any obligation to update or keep current the information contained in this presentation and any opinions
expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, currency, accuracy, reasonableness or completeness of the
information contained herein. Neither Imagion nor any other person (including its shareholders, directors, officers and employees) accepts any liability and Imagion, its shareholders, its related bodies corporate
and their respective directors, officers and employees, to the maximum extent permitted by law, expressly disclaim all liabilities for any loss howsoever arising, directly or indirectly, from this presentation or its
contents.
This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current expectations concerning, among other things, Imagion's results of operations, financial condition,
performance, prospects, growth, strategies and the industry in which Imagion operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors, many of which are
beyond the control of Imagion. Imagion cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition, performance,
prospects, growth or opportunities and the development of the industry in which Imagion operates may differ materially from those made in or suggested by the forward-looking statements contained in this
presentation. In addition, Imagion does not guarantee any particular rate of return or the performance of Imagion nor does it guarantee the repayment or maintenance of capital or any particular tax treatment.
Investors should note that past performance may not be indicative of results or developments in future periods and cannot be relied upon as an indicator of (and provides no guidance as to) Imagion's future
performance. Imagion, its related bodies corporate and each of their respective directors, officers and employees and advisers expressly disclaim any obligation or undertaking to review, update or release any
update of or revisions to any forward-looking statements in this presentation or any change in Imagion's expectations or any change in events, conditions or circumstances on which these forward-looking
statements are based, except as required by applicable law or regulation.
This presentation and any materials distributed in connection with this presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any
locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such
jurisdiction.
The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe any such restrictions.
IMAGIONBIOSYSTEMS.COM | 13
Contact:
www.imagionbiosystems.com
info@imagionbio.com
ASX: IBX
Share your feedback
Discover